Get started
Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals, Inc.Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

No trades
OverviewFinancialsNewsCommunityTechnicalsForecastsSeasonalsBondsETFs

What traders are saying


Join the conversation. Discover trade ideas, share insights, and see how others read the market.
REGN - Technical Pullback Setup with Strong Fundamentals📈 TRADE SETUP Direction: LONG Entry: $799.20 (current retracement zone) Stop Loss: $740.00 Take Profit: $917.60 Risk/Reward: ~1:2.0 Time Horizon: 6–12 weeks 🧠 TECHNICAL RATIONALE ✅ Multi-Timeframe Structure Daily: Primary uptrend intact; currently pulling back to dynamic support 4H: Bullish structure holding above key moving averages 1H: Short-term oversold, suggesting potential for bounce Volume: Declining on pullback — indicates lack of aggressive selling 📊 Indicator Analysis RSI (14): ~60.1 — Healthy pullback from overbought, room for upside resumption MACD: Bullish on daily but recent pullback in histogram; watching for bullish crossover Moving Averages: Price near 20-day SMA ($757.50) — key dynamic support 50-day SMA ($718.50) acting as major trend support Bollinger Bands: Price retesting middle band — common bounce zone in uptrends 🔁 Connors RSI2 Context 1 recent buy signal (Dec 31) — confirmed oversold bounce already occurred Suggests initial reversal may be underway; watching for follow-through 📍 KEY LEVELS Immediate Support: $785–$795 (current retracement zone + 20-day SMA confluence) Strong Support: $740 (below recent swing low & 50-day SMA) Resistance: $850 (previous high), $917.60 (measured move extension) 🛠️ TRADE MANAGEMENT Entry Plan Current Zone Entry: $795–$805 on bullish reversal candle or RSI divergence Confirmed Entry: Wait for 4-hour close above $810 for momentum confirmation Stop Loss Hard Stop: $740.00 (below 50-day SMA and recent swing structure) Trailing Stop: Move to breakeven at $850, then trail using 20-day SMA Take Profit TP1: $850 (previous resistance & partial profit zone) TP2: $917.60 (Fibonacci extension & primary target) ⚠️ RISK DISCLOSURE This is not financial advice. Trading involves substantial risk of loss. Past performance does not guarantee future results. Always conduct your own analysis and manage risk appropriately. Ticker: REGN Timeframe: Daily + 4H Strategy: Swing Long on Trend Pullback Published: January 6, 2025 #REGN #Regeneron #Biotech #SwingTrading #Pullback #Pharmaceuticals #TechnicalAnalysis #TradingView #ChartAlert #HealthcareStocks #TrendFollowing #RiskManagement
NASDAQ:REGNLong
by shortermtrader
REGN | Regeneron Pharmaceuticals – Macro Reaccumulation SetupPublished by WaverVanir International LLC | 06/12/2025 Regeneron has completed a deep retracement, touching the 0.886 Fibonacci level (~$567) and entering a strong discount zone, coinciding with a weak low sweep and increasing volume — suggesting potential accumulation by institutions. 🔍 Key Confluences: 🔄 Internal CHoCH and BOS structure shift indicates short-term reversal 🔵 Entered macro discount territory with a clean sweep of liquidity below $485 🟡 Targeting major inefficiency and liquidity void around $766.75, aligning with 0.5 retracement and prior equilibrium 🟥 Supply zones between $640–$720 may offer resistance/partial profit-taking zones 📉 Risk Framework: Entry consideration: $500–$520 Stop loss idea: Below $475 (invalidate weak low sweep) Primary Target: $766.75 Secondary Target (Extended): $818–$852 🧠 Fundamental & Macro Watch: Upcoming trial results or FDA action could act as a key catalyst Biotech sector sentiment tied to macro healthcare policy and AI-integration for drug discovery Recent earnings showed strong forward guidance – potential re-rating ahead 📈 Probabilistic Outlook: Bullish retracement toward $766.75: 70% Extended bearish continuation (below $485): 15% Sideways chop: 15% 🧭 Smart money often reacts to extreme fear – REGN may be entering a mark-up phase if confirmed with institutional follow-through. #REGN NASDAQ:REGN #SmartMoneyConcepts #FibConfluence #WaverVanir #BiotechStocks #SwingTrading #TechnicalAnalysis #InstitutionalOrderFlow
NASDAQ:REGNLong
by Wavervanir_International_LLC
Regeneron (REGN): Bullish Momentum Approved for DupixentRegeneron Pharmaceuticals ( NASDAQ:REGN ) is exhibiting a powerful bullish surge, a move catalyzed by significant fundamental news. This momentum is expected to propel the stock toward its defined technical targets. The primary driver is the recent decision by the European Commission (EC) to approve Regeneron and Sanofi's blockbuster drug, Dupixent (dupilumab), for the treatment of chronic spontaneous urticaria (CSU). This authorization is a substantial milestone, as it marks the first targeted therapy approved for this skin condition in the European Union in over a decade. CSU is a chronic and often debilitating inflammatory skin disease characterized by sudden, unpredictable hives and intense itch. While typically first treated with H1-antihistamines (H1AH), a substantial population of an estimated 270,000 patients in the EU alone continues to suffer from inadequate symptom control. Dupixent now offers a novel mechanism of action for these patients, as it is the only approved therapy that works by inhibiting two key proteins, IL-4 and IL-13, which are central drivers of the type 2 inflammation underlying CSU. This major regulatory expansion for one of its flagship products has ignited a strong bullish momentum in NASDAQ:REGN , breaking the stock out of its previous consolidation. The technical structure now appears exceptionally robust, providing a clear roadmap for the anticipated upward move. The chart reveals two critical Fibonacci-based support levels that should serve as foundations for this new leg higher: The primary support rests at the 0.618 Fibonacci level, corresponding to $630.39. This is a key zone where buyers have previously stepped in aggressively. A secondary, deeper support level is identified at the 0.786 Fibonacci level, near $472.49. A retracement to this level would represent a more significant pullback but would likely find strong institutional interest. On the upside, the path is defined by two clear take-profit targets, measured using Fibonacci extension levels: The first profit target is set at the 0.382 level, which aligns with $852.18. This represents a significant resistance zone and a logical initial objective for the current bullish impulse. The secondary and more ambitious target is projected at the 0.236 level, at $989.40. A move to this level would signify a powerful, sustained breakout and capture the majority of the trend. In summary, the confluence of a major positive regulatory catalyst for its key growth driver, Dupixent, and a technically sound chart setup with well-defined support and resistance zones, creates a highly compelling bullish case for Regeneron. The momentum is substantial, and the stock is well-positioned to reach its initial price targets in a relatively short timeframe.
NASDAQ:REGNLong
by KalaGhazi
Earnings playREGN’s chart shows a classic dip in a long-term uptrend, with FDA tailwinds and undervaluation (14x PE vs. sector 25x) making it a compelling buy. The $560–$570 zone offers a low-risk entry ahead of earnings, where a beat could ignite a 20–30% rally to $700+. Buy on dip for 10–15% short-term gain, with 20–30% upside post-earnings if catalysts hit Oct 28. Eps will be lower due to $83 million acquired in-process R&D charge. Some caution on Eylea erosion, but sentiment leans bullish, tight risk management advised.
NASDAQ:REGNLong
by WSMS199
Can Innovation Survive Manufacturing Chaos?Regeneron Pharmaceuticals stands at a fascinating crossroads, embodying the paradox of modern biotechnology: extraordinary scientific achievement shadowed by operational vulnerability. The company has successfully transformed from a blockbuster-dependent enterprise into a diversified biopharmaceutical powerhouse, driven by two key engines. Dupixent continues its remarkable ascent, achieving 22% growth and reaching $4.34 billion in Q2 2025. Meanwhile, the strategic transition from legacy Eylea to the superior Eylea HD demonstrates forward-thinking market positioning, despite apparent revenue declines. The company's innovation engine supports its aggressive R&D strategy, investing 36.1% of revenue, nearly double the industry average, into discovery and development. This approach has yielded tangible results, with Lynozyfic's FDA approval marking Regeneron's first breakthrough in blood cancer, achieving a competitive 70% response rate in multiple myeloma. The proprietary VelociSuite technology platform, particularly VelocImmune and Veloci-Bi, creates a sustainable competitive moat that competitors cannot easily replicate, enabling the consistent generation of fully human antibodies and differentiated bispecific therapies. However, Regeneron's scientific triumphs are increasingly threatened by third-party manufacturing dependencies that have created critical vulnerabilities. The FDA's second rejection of odronextamab, despite strong European approval and compelling clinical data, is due to manufacturing issues at an external facility, rather than scientific deficiencies. This same third-party bottleneck has delayed crucial Eylea HD enhancements, potentially allowing competitors to gain market share during a pivotal transition period. The broader strategic landscape presents both opportunities and risks that extend beyond manufacturing concerns. Although the company's strong victories in intellectual property cases against Amgen and Samsung Bioepis showcase effective legal defenses, the proposed 200% drug tariffs and industry-wide cybersecurity breaches, such as the Cencora incident impacting 27 pharmaceutical companies, highlight significant systemic vulnerabilities. Regeneron's fundamental strengths-its technological platforms, diverse pipeline spanning oncology to rare diseases, and proven ability to commercialize breakthrough therapies-position it for long-term success, provided it can resolve the operational dependencies that threaten to derail its scientific achievements.
NASDAQ:REGNLong
by UDIS_View
REGN Weekly Trade Setup – High Conviction Put Play 🎯 **REGN Weekly Trade Setup – High Conviction Put Play** 📌 **Instrument:** REGN 📉 **Direction:** PUT (SHORT) 💵 **Strike:** \$580 💰 **Entry Price:** \$5.20 🏹 **Profit Target:** \$10.40 🛑 **Stop Loss:** \$7.80 📅 **Expiry:** 2025-08-20 📏 **Size:** 1 💪 **Confidence:** 65% ⏰ **Entry Timing:** Market Open ⚠️ **Key Risks:** * Only 2 days to expiry → high gamma risk * Rapid price swings possible due to institutional activity or news * Mixed signals on options flow & volume ✅ **Rationale:** * Bullish RSI momentum tempered by bearish options flow * High put activity supports short positioning * Risk/reward favors aggressive yet measured play 🔥 **TradingView / Social Tags:** \#REGN #OptionsTrading #PutOptions #WeeklyOptions #ShortTrade #BearishSetup #TechnicalAnalysis #HighConvictionTrade #GammaRisk #PriceAction #TradingSignals #MarketAnalysis #RiskManagement #OptionsFlow #TradingStrategy
NASDAQ:REGNShort
by quantsignals
Regeneron Pharmaceuticals | REGN | Long at $502.28Regeneron Pharmaceuticals NASDAQ:REGN stock dropped more than 17% today due to mixed Phase 3 trial results for itepekimab, a potential COPD drug. However, the company has an extensive drug pipeline, raked in over $14 billion last year, and is currently trading at a price-to-earnings of 15x. Debt-to-equity is 0.09x (extremely healthy) and earnings are forecast to grow 7.5% per year. While 2025 is anticipated to be its "worst" earnings year, the outlook through 2028 looks like steady growth in revenue and cash flow. From a technical analysis view, the stocks entered my "crash" simple moving average zone today (currently between $466 and $502). More often than not, this area signals a bottom in the near-term, but it's not guaranteed. I wouldn't be surprised if the $450s-$460s get hit before a reversal if the market shifts negatively - which will be another entry for me. If it moves into my "major" crash zone in the $300s to close more gaps on the daily chart, I will be piling into this stock heavily (like I did with NYSE:UNH ) for a longer-term hold - of course, unless fundamentals change. I'm going to keep my target small unless there is a "major crash" and eye the closing of the nearest price gap on the daily. There is another between $883-$914... Targets: $590 (+17.5%)
NASDAQ:REGNLong
by WorthlessViews
1
Regeneron Pharmaceuticals Q2-Q3 Confirmed "Troughing in ProgressIF we do not crash like many Elliottsions are suggesting implying of Grand 5th wave since 1929... iF we do not start WW3... IF everything utterly absolute out there in the pharmaceutical industries locally and globally... IF our studies of the relation between XLV and Regeneron Pharmaceuticals is remotely correct... Then we should have struck a trough or we shall see one in the next few months Q2-Q4 = We will see a big bullish move next ! *** Risk down is (-35%) ...
NASDAQ:REGN
by samitrading
REGN – Bullish Engulfing + RSI Divergence at Weekly DemandRegeneron (REGN) is showing strong technical signals of potential reversal from a key weekly demand zone, replicating a setup similar to March 2021. 🔹 Bullish Engulfing Candle forms directly at the demand zone after a multi-month downtrend. 🔹 Volume Spike confirms strong buyer interest. 🔹 RSI shows bullish divergence, breaking its internal structure and holding above 30. 🔹 MACD crossover is setting up, with histogram and signal lines echoing the same configuration from March 2021 — which led to a significant rally. This is a textbook confluence setup: Structure (demand zone) Momentum (RSI divergence) Confirmation (volume + engulfing) Trigger alignment (MACD timing) A decisive follow-through above recent highs could confirm the reversal and initiate a new bullish leg.
NASDAQ:REGNLong
by fredcast80
4
REGN Technical Analysis: Potential Bullish SetupREGN is currently at a strong weekly support level, having formed a double bottom with a clear bullish divergence on the daily chart. The price has also closed above a downward trendline, signaling a potential shift in momentum. While the price might be slightly resistant in the 668 - 686 zone, a strong close above this area could lead to further upside. Trading Recommendations: Entry Point (CMP): 594 Stop-Loss: Closing below 520 Take Profit 1: 686 Take Profit 2: Open Beyond the initial target, other potential targets include 740. After that, the price could look to fill a gap at 914, and potentially even hit 1200 as there appears to be no major resistance before that level. Happy trading!
NASDAQ:REGNLong
by TradeWithParas